Dentsply Sirona Set to Report Q1 2026 Earnings May 5 Amid Missed Estimates and Soft U.S. Demand

In the most recent quarter, XRAY’s earnings missed the Zacks consensus estimate by 3.57%, though its average surprise over the prior four quarters was 7.73%. The firm is in the early stage of its multi‑year “Return‑to‑Growth” plan, which includes higher spending on innovation, commercial reorganization and clinical education. These investments are pressuring margins as U.S. demand for equipment, implants and CAD/CAM solutions remains soft and tariff‑related costs linger.

- XRAY ticker: XRAY; recent close $23.45, down 2.1% over the past week; market cap ≈ $6.8 billion. - Consensus revenue forecast for Q1 2026: $840.1 million; consensus EPS: $0.28. - Internal model revenue forecast: $846.2 million; internal EPS forecast: $0.32. - Prior quarter earnings shortfall: –3.57% vs. Zacks estimate. - Four‑quarter average earnings surprise: +7.73%.

The gap between the consensus and internal outlook suggests the company anticipates stronger performance than Wall Street expects, possibly reflecting confidence in the Return‑to‑Growth initiatives. However, continued U.S. softness, dealer inventory adjustments (about $30 million of stock to be worked down in H1 2026) and tariff headwinds could keep revenue growth muted. International markets, especially Europe, may provide offsetting stability. Investors will look for signs that dealer reengagement is improving and that margin pressure is easing as the transformation plan progresses. Watch for sequential improvement in the second half of 2026, updates on dealer partnership execution, and any early traction from the implants and commercial restructuring efforts.